aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke.
bSUSTAIN 7 included 0.5 mg and 1 mg doses for Ozempic® and 0.75 mg and 1.5 mg doses for Trulicity®.
cWeight change was a secondary endpoint in clinical trials.
dResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial for patients with T2D and established CVD.
T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MI=myocardial infarction.